Combined inhibition of EGFR and RAF1 for mutant-KRAS, mutant TP53-driven PDAC

DISEASE CATEGORY: Cancer

INDICATION: Pancreatic cancer

Cell culture and mouse studies suggest dual inhibition of EGFR and CRAF could help treat KRAS- and p53-mutant pancreatic ductal adenocarcinoma

Read the full 262 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE